# Razelle Kurzrock

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/razelle-kurzrock/

## Facts

| Field | Value |
| --- | --- |
| Citations | 89,112 |
| Field | Cancer Genomics and Diagnostics |
| h-index | 145 |
| i10-index | 894 |
| Last Known Institution | Froedtert Hospital |
| OpenAlex ID | https://openalex.org/A5053481267 |
| ORCID iD | https://orcid.org/0000-0003-4110-1214 |
| Works | 2,331 |

## Researcher papers

- [Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers](https://scholariq.org/papers/tumor-mutational-burden-as-an-independent-predictor-of-response-to-immunotherapy/)
- [PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy](https://scholariq.org/papers/pd-l1-expression-as-a-predictive-biomarker-in-cancer-immunotherapy/)
- [International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease](https://scholariq.org/papers/international-evidence-based-consensus-diagnostic-criteria-for-hhv-8-negative/)
- [Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial](https://scholariq.org/papers/genomic-and-transcriptomic-profiling-expands-precision-cancer-medicine-the/)
- [Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial](https://scholariq.org/papers/safety-pharmacokinetic-pharmacodynamic-and-efficacy-data-for-the-oral-mek/)
- [Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial](https://scholariq.org/papers/activity-of-the-oral-mek-inhibitor-trametinib-in-patients-with-advanced-melanoma/)
- [Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative](https://scholariq.org/papers/personalized-medicine-in-a-phase-i-clinical-trials-program-the-md-anderson/)
- [International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease](https://scholariq.org/papers/international-evidence-based-consensus-treatment-guidelines-for-idiopathic/)
- [Analysis of <i>NTRK</i> Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics](https://scholariq.org/papers/analysis-of-i-ntrk-i-alterations-in-pan-cancer-adult-and-pediatric-malignancies/)
- [Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors](https://scholariq.org/papers/phase-i-study-of-ro4929097-a-gamma-secretase-inhibitor-of-notch-signaling-in/)
- [International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease](https://scholariq.org/papers/international-evidence-based-consensus-diagnostic-and-treatment-guidelines-for/)

## Researcher topics

- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)

## Researcher university

- [Froedtert Hospital](https://scholariq.org/institutions/froedtert-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.